Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2007
Date:11/9/2007

305

Adjusted EBITDA of Warner

Chilcott Holdings

Company III, Ltd., as

defined $126,027 $96,924 $335,842 $278,490

Note: Warner Chilcott Holdings Company III, Limited and certain of its subsidiaries are parties to our credit agreement and the indenture governing our Senior Subordinated Notes due 2015. Certain expenses included in Warner Chilcott Limited's consolidated operating results are not deducted in arriving at Adjusted EBITDA for Warner Chilcott Holdings Company III, Ltd and its subsidiaries.

WARNER CHILCOTT LIMITED

REVENUE BY PRODUCT

(In millions of U.S. dollars)

(Unaudited)

Quarter Ended Nine Months Ended

Sept-30-07 Sept-30-06 Sept-30-07 Sept-30-06

Oral Contraception ("OC")

LOESTRIN 24 FE $38.2 $15.1 $107.3 $22.7

FEMCON FE 9.4 - 20.8 -

ESTROSTEP FE 17.9 25.5 60.1 79.0

OVCON 35/50 5.2 21.3 12.1 68.5

Total OC 70.7 61.9 200.3 170.2

Hormone therapy ("HT")

ESTRACE Cream 18.2 15.5 52.9 48.1

FEMHRT 16.8 15.1 47.3 41.7

FEMRING 3.4 2.8 10.7 7.9

ESTRACE Tablets 2.5 1.7 7.6 5.4

FEMTRACE 1.0 1.0 3.2 2.0

Total HT 41.9 36.1 121.7 105.1

Dermatology

DOVONEX 32.0 35.9 107.4 109.6

TACLONEX
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Virginia Faith Leaders Call on Senators Webb & Warner to Cosponsor Legislation to Protect Kids from Tobacco
2. Warner Chilcott and NexMed Sign U.S. Collaboration for Topical Alprostadil Treatment for Erectile Dysfunction
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 1H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 2H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 3Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 1Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 2PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 1PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 2